"Biomarkers, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS.
| Descriptor ID |
D014408
|
| MeSH Number(s) |
D23.101.140
|
| Concept/Terms |
Biomarkers, Tumor- Biomarkers, Tumor
- Tumor Biomarkers
- Markers, Biological Tumor
- Tumor Markers, Biological
- Markers, Tumor Metabolite
- Tumor Metabolite Markers
- Metabolite Markers, Tumor
- Marker, Tumor Metabolite
- Metabolite Marker, Tumor
- Tumor Metabolite Marker
- Tumor Markers, Biologic
- Biologic Tumor Markers
- Markers, Biologic Tumor
- Marker, Biologic Tumor
- Biologic Tumor Marker
- Tumor Marker, Biologic
- Biochemical Tumor Markers
- Markers, Biochemical Tumor
- Marker, Biochemical Tumor
- Biochemical Tumor Marker
- Tumor Marker, Biochemical
- Tumor Markers, Biochemical
- Carcinogen Markers
- Markers, Carcinogen
- Markers, Neoplasm Metabolite
- Neoplasm Metabolite Markers
- Marker, Neoplasm Metabolite
- Metabolite Marker, Neoplasm
- Neoplasm Metabolite Marker
- Metabolite Markers, Neoplasm
- Biological Tumor Markers
- Biological Tumor Marker
- Tumor Marker, Biological
- Marker, Biological Tumor
Markers, Tumor- Markers, Tumor
- Tumor Markers
- Biomarkers, Cancer
- Cancer Biomarkers
|
Below are MeSH descriptors whose meaning is more general than "Biomarkers, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Biomarkers, Tumor".
This graph shows the total number of publications written about "Biomarkers, Tumor" by people in this website by year, and whether "Biomarkers, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 2 | 3 |
| 1997 | 3 | 7 | 10 |
| 1998 | 2 | 4 | 6 |
| 1999 | 2 | 8 | 10 |
| 2000 | 2 | 11 | 13 |
| 2001 | 3 | 11 | 14 |
| 2002 | 8 | 5 | 13 |
| 2003 | 6 | 11 | 17 |
| 2004 | 12 | 14 | 26 |
| 2005 | 13 | 9 | 22 |
| 2006 | 16 | 13 | 29 |
| 2007 | 13 | 15 | 28 |
| 2008 | 23 | 18 | 41 |
| 2009 | 21 | 25 | 46 |
| 2010 | 14 | 19 | 33 |
| 2011 | 26 | 29 | 55 |
| 2012 | 29 | 18 | 47 |
| 2013 | 29 | 29 | 58 |
| 2014 | 17 | 24 | 41 |
| 2015 | 31 | 32 | 63 |
| 2016 | 25 | 35 | 60 |
| 2017 | 33 | 32 | 65 |
| 2018 | 33 | 35 | 68 |
| 2019 | 50 | 34 | 84 |
| 2020 | 44 | 28 | 72 |
| 2021 | 29 | 36 | 65 |
| 2022 | 3 | 28 | 31 |
| 2023 | 1 | 20 | 21 |
| 2024 | 22 | 39 | 61 |
| 2025 | 31 | 19 | 50 |
| 2026 | 1 | 5 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biomarkers, Tumor" by people in Profiles.
-
Stage I Triple-Negative Breast Cancer: Moving From One-Size-Fits-All to a Personalized Approach. Am Soc Clin Oncol Educ Book. 2026 Jun; 46(3):e520666.
-
Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer. Sci Transl Med. 2026 Apr 22; 18(846):eaec2358.
-
Personalizing Curative Therapy in Stage II to III Triple-Negative Breast Cancer. Am Soc Clin Oncol Educ Book. 2026 Jun; 46(3):e520834.
-
Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape. Am Soc Clin Oncol Educ Book. 2026 Jun; 46(3):e520506.
-
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease. J Clin Oncol. 2026 May 10; 44(14):1283-1295.
-
Triple negative breast cancer: what clinical progress have we seen in the last 5?years? Expert Opin Investig Drugs. 2026 Mar; 35(3):223-238.
-
Clinical applications of mass spectrometry in multiple myeloma. Blood Adv. 2025 Dec 23; 9(24):6593-6603.
-
Papillary renal cell carcinoma, formerly known as Type 2: a single institutional study addressing histologic and molecular features. Histopathology. 2026 Apr; 88(5):1044-1050.
-
Identifying and mitigating the biological effectors of the social determinants of health in cancer. J Natl Cancer Inst. 2025 Oct 01; 117(10):1981-1983.
-
Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology). Leukemia. 2025 Dec; 39(12):2926-2934.